Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

Red Blood Cell

Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.

OTHER

Standard of care

NHLBI/ASH/ATS Expert Panel recommended guidelines

Trial Locations (23)

10029

Icahn School of Medicine at Mount Sinai, New York

10461

Montefiore Medical Center, New York

15232

University of Pittsburgh Medical Center, Pittsburgh

20060

Howard University Center for Sickle Cell Disease, Washington D.C.

21201

University of Maryland, Baltimore

21206

Johns Hopkins University, Baltimore

23284

Virginia Commonwealth University, Richmond

27599

University of North Carolina at Chapel Hill, Chapel Hill

27708

Duke University, Durham

27834

East Carolina University, Greenville

28204

Atrium Health, Charlotte

30322

Emory University, Atlanta

35401

University of Alabama, Tuscaloosa

43210

Ohio State University, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

60607

University of Illinois at Chicago, Chicago

63110

Washington University-St. Louis, St Louis

77030

University of Texas Health Science Center at Houston, Houston

94609

UCSF Benioff Children's Hospital Oakland, Oakland

02118

Boston Medical Center, Boston

Unknown

Hemorio, Rio de Janeiro

Kremlin-Bicêtre, Créteil

Henri Mondor Hopital, Paris

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Pittsburgh

OTHER